Archive: October 2022

Treatment of Amyloid Light Chain Cardiac Amyloidosis: Systematic Review and Future Directions

Abstract: Background: Several treatment strategies for amyloid light chain cardiac amyloidosis (AL-CA) have been described in the literature; however, there is no consensus about the optimal […]

Current and Emerging Options for Patients With Melanoma Brain Metastases

Abstract: Melanoma is the most aggressive skin cancer, with a high incidence of metastatic spread and a predilection for metastases to the brain. It represents the […]

Prevention and Treatment of Venous Thromboembolism in Primary and Metastatic Brain Cancer

H&O  How many people develop brain cancer each year in the United States, and which types of cancer are most likely to lead to brain metastases?  […]

Nivolumab and Relatlimab as Frontline Therapy in Advanced Melanoma

H&O  What makes the combination of nivolumab and relatlimab a good choice in advanced melanoma? NK  We already have a wealth of data on monotherapy with […]

Advances in the Classification and Management of Patients With T-Cell Lymphoma

H&O What are the most common types of T-cell lymphoma? LP  T-cell lymphoma is a heterogeneous group of disorders that encompass many subtypes. T-cell lymphomas that […]

Letter From the Editor: There Has to Be a God . . .

Evolution is described as the ultimate and inevitable result of random mutations occurring over successive generations, leading to functional improvements in organisms that provide a survival […]

The Clinical Importance of Prognostic Markers in CLL

H&O  How has the role of prognostic markers in chronic lymphocytic leukemia (CLL) changed with the transition from standard chemoimmunotherapy drugs to targeted agents?  JA  Since […]

Back to Archive